# A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

> **NCT06610526** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 731 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06610526
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 731 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06610526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06610526, "A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06610526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*